The association of partial pressures of oxygen and carbon dioxide with neurological outcome after out-of-hospital cardiac arrest: an explorative International Cardiac Arrest Registry 2.0 study by Ebner, Florian et al.
ORIGINAL RESEARCH Open Access
The association of partial pressures of
oxygen and carbon dioxide with
neurological outcome after out-of-hospital
cardiac arrest: an explorative International
Cardiac Arrest Registry 2.0 study
Florian Ebner1* , Richard R. Riker2, Zana Haxhija2, David B. Seder2, Teresa L. May2, Susann Ullén3, Pascal Stammet4,
Karen Hirsch5, Sune Forsberg6, Allison Dupont7, Hans Friberg8, John A. McPherson9, Eldar Søreide10,11,
Josef Dankiewicz12, Tobias Cronberg13 and Niklas Nielsen1
Abstract
Background: Exposure to extreme arterial partial pressures of oxygen (PaO2) and carbon dioxide (PaCO2) following
the return of spontaneous circulation (ROSC) after out-of-hospital cardiac arrest (OHCA) is common and may affect
neurological outcome but results of previous studies are conflicting.
Methods: Exploratory study of the International Cardiac Arrest Registry (INTCAR) 2.0 database, including 2162 OHCA
patients with ROSC in 22 intensive care units in North America and Europe. We tested the hypothesis that exposure to
extreme PaO2 or PaCO2 values within 24 h after OHCA is associated with poor neurological outcome at discharge. Our
primary analyses investigated the association between extreme PaO2 and PaCO2 values, defined as hyperoxemia (PaO2 > 40
kPa), hypoxemia (PaO2 < 8.0 kPa), hypercapnemia (PaCO2 > 6.7 kPa) and hypocapnemia (PaCO2 < 4.0 kPa) and neurological
outcome. The secondary analyses tested the association between the exposure combinations of PaO2 > 40 kPa with
PaCO2 < 4.0 kPa and PaO2 8.0–40 kPa with PaCO2 > 6.7 kPa and neurological outcome. To define a cut point for the onset of
poor neurological outcome, we tested a model with increasing and decreasing PaO2 levels and decreasing PaCO2 levels.
Cerebral Performance Category (CPC), dichotomized to good (CPC 1–2) and poor (CPC 3–5) was used as outcome measure.
Results: Of 2135 patients eligible for analysis, 700 were exposed to hyperoxemia or hypoxemia and 1128 to hypercapnemia
or hypocapnemia. Our primary analyses did not reveal significant associations between exposure to extreme PaO2 or PaCO2
values and neurological outcome (P= 0.13–0.49). Our secondary analyses showed no significant associations between
combinations of PaO2 and PaCO2 and neurological outcome (P= 0.11–0.86). There was no PaO2 or PaCO2 level significantly
associated with poor neurological outcome. All analyses were adjusted for relevant co-variates.
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Conclusions: Exposure to extreme PaO2 or PaCO2 values in the first 24 h after OHCA was common, but not independently
associated with neurological outcome at discharge.
Keywords: Oxygen, Carbon dioxide, Out-of-hospital cardiac arrest, Brain anoxia-ischemia, Cardio-pulmonary resuscitation,
Critical care outcomes
Introduction
Admission to hospital as well as 30-day survival after
out of hospital cardiac arrest (OHCA) has increased in
recent years and most 30-day survivors after OHCA are
discharged with good neurological function [1]. Despite
these advances, the proportion of patients dying after
hospital admission is more than 50 % and the major
causes are the primary ischemic cerebral injury sustained
during the no-flow time of the OHCA and the additional
secondary cerebral reperfusion injury that commences at
return of spontaneous circulation (ROSC) [2, 3]. Reper-
fusion entails increased reactive oxygen species (ROS)
production, mitochondrial dysfunction and apoptosis,
and thus, exacerbates the detrimental consequences of
the OHCA [3]. Targeted temperature management
(TTM) has been suggested as an intervention to attenu-
ate these effects but studies are inconclusive and current
studies indicate varying use internationally [4–8]. Recent
data suggest that elevated arterial partial pressure of car-
bon dioxide (PaCO2), hypercapnemia, might improve
neurological outcome after OHCA. Possible underlying
mechanisms include decreased cerebral vascular resist-
ance (CVR), increased cerebral blood flow (CBF), modu-
lation of inflammatory processes and anti-convulsive
properties [9–16]. In contrast to hypercapnemia, low
PaCO2, hypocapnemia, increases CVR, decreases CBF,
reduces oxygen delivery (CDO2) and is associated with
poor outcome [10, 16–19]. Low arterial partial pressure
of oxygen (PaO2), hypoxemia, is the primary source of
neuronal injury occurring during the OHCA and a de-
terminant of neurological outcome [3, 20]. Elevated
PaO2, hyperoxemia, has also been associated with poor
neurological outcome, possibly due to increased lipid
oxidation, production of ROS, mitochondrial damage
and reduced CBF [3, 21–23]. The association of combi-
nations of extreme PaO2 and PaCO2 values after OHCA
with outcome have less frequently been studied, but the
combination of moderate hypercapnemia and mild
hyperoxemia was association with improved neurological
outcome in one study [24]. Overall study results are in-
consistent and other investigations trying to confirm the
protective or harmful associations of exposure to ex-
treme PaO2 and PaCO2 values with neurological out-
come were unable to do so [25–27]. Moreover, the
available studies differ in methodology, inclusion criteria
and may lack sufficient power. Therefore, we conducted
this study of the International Cardiac Arrest Registry
(INTCAR) 2.0 database to investigate the association be-
tween exposure to extreme PaCO2 and PaO2 values and
neurological outcome at hospital discharge in a large co-
hort of adult, unconscious patients with sustained ROSC
after OHCA.
Methods
INTCAR 2.0 is an international multicenter database in-
cluding cardiac arrest patients admitted to intensive care
units (ICU) at 22 medical centers in the United States and
Europe. The present investigation of the INTCAR 2.0
database included prospectively collected cardiac arrest
and treatment data from adult (≥18 years of age), uncon-
scious (GCS < 8), OHCA patients with sustained ROSC.
All patients in this study received TTM treatment and
were admitted between 2008 and 2018. Patient data col-
lected in the database was anonymized and OHCA data
was reported according to the Utstein-style protocol [28].
Ethical committees in each participating country approved
the data collection and analysis. Informed consent was ei-
ther waived or obtained from all participants or relatives
according to national and local standards, in line with the
Helsinki declaration. Reporting of our analyses was guided
by the STROBE recommendations [29].
Definition of PaO2 and PaCO2 groups and data
registration
In the INTCAR 2.0 protocol, extreme PaO2 or PaCO2
exposure thresholds were defined as PaO2 > 40 kPa,
PaO2 < 8.0 kPa, PaCO2 > 6.7 kPa and PaCO2 < 4.0 kPa.
Exposure to one or more extreme values during the first
24 h after ROSC was registered in a dichotomous man-
ner (yes/no). The PaO2 and PaCO2 thresholds were
aligned with previous studies [17, 21, 22]. Additionally,
the single highest and lowest PaO2 values and the lowest
PaCO2 value during the first 24 h after ROSC were doc-
umented, regardless of exposure level. In total 7 data-
points (4 PaO2 and 3 PaCO2 data-points) were collected
per patient. For the purpose of this study we divided pa-
tients according to their extreme PaO2 or PaCO2 value
exposure into four groups defined by the extreme values
in the INTCAR 2.0 protocol; hyperoxemia (PaO2 > 40
kPa), hypoxemia (PaO2 < 8.0 kPa), hypercapnemia
(PaCO2 > 6.7 kPa) and hypocapnemia (PaCO2 < 4.0 kPa).
Patients not exposed to extreme values were classified as
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PaO2 and PaCO2 no-exposure (PaO2 8.0–40 kPa and
PaCO2 4.0–6.7 kPa). Patients exposed to more than one
extreme value were included in all exposure groups.
Outcome
To better compare with previous analyses [21, 22, 27, 30],
cerebral performance category (CPC) at discharge from hos-
pital was chosen as primary outcome endpoint. After neuro-
logical assessment at hospital discharge by a trained health
care professional OHCA patients were allocated to one of
the five CPC categories, ranging from CPC1 (good cerebral
performance/mild disability), CPC2 (moderate disability),
CPC3 (severe disability), CPC4 (coma state) and CPC5 (brain
death) [31, 32]. For this study we dichotomized outcome into
good (CPC1 and 2) and poor (CPC3–5). Delayed outcomes,
typically around 6months after presentation, were also col-
lected, by telephone interview or medical records.
In our primary analysis, we tested the association of ex-
posure to extreme PaO2 or PaCO2 values with outcome.
We conducted 8 analyses: 1.the hyperoxemia group was
compared to the PaO2 no-exposure group and 2.to patients
without hyperoxemia (no-hyperoxemia). The hypoxemia
group was compared 3.to the PaO2 no-exposure group and
4.to patients not exposed to hypoxemia (no-hypoxemia).
Patients in the hypercapnemia group were compared 5.to
patients in the PaCO2 no-exposure group and 6.to patients
without hypercapnemia exposure (no-hypercapnemia),
while patients with hypocapnemia exposure were compared
7.to the PaCO2 no-exposure group and 8.to patients not ex-
posed to hypocapnemia (no-hypocapnemia).
In previous studies, exposure to hyperoxemia, hypox-
emia and hypocapnemia were associated with poor out-
come while hypercapnemia was associated with good
outcome [13, 18, 21, 22]. In our secondary analyses we
therefore, a priori, defined exposure groups to investi-
gate these findings and compared patients exposed to
the combination of hyperoxemia with hypocapnemia to
a PaO2 and PaCO2 no-exposure group, followed by a
PaO2 no-exposure group with hypercapnemia compared
to the PaO2 and PaCO2 no-exposure group. Subse-
quently, we designed regression models with ascending
and descending PaO2 values from < 20 kPa to > 60 kPa
and > 8.0 kPa to < 5.0 kPa to define a possible threshold
for the onset of the association of hyperoxemia or hyp-
oxemia and poor outcome. We also designed a regres-
sion model for the onset of the association of
hypocapnemia and poor outcome with descending
PaCO2 values from > 4.0 kPa to < 3.5 kPa.
Sensitivity analyses
Sensitivity analyses were performed for our primary ana-
lyses with all double exposed patients (hyperoxemia and
hypoxemia or hypercapnemia and hypocapnemia) re-
moved. Furthermore, we performed sensitivity analyses
of our primary analyses, replacing outcome at discharge
with long-term outcome at 6-month follow-up.
Statistical analysis
Proportions are presented as numbers and percentages
and continuous variables as means with standard devia-
tions (SD) or medians with interquartile ranges (IQR). Lo-
gistic regression analysis was used to assess the
association between PaO2 and PaCO2 and neurological
outcome at discharge. For the ascending analysis the odds
ratio (OR) above the threshold was compared to the OR
under the threshold, while for the descending analyses the
OR under the threshold was compared to the OR above
the threshold. All analyses were adjusted for pre-specified,
and OHCA relevant co-variates: age (years), sex (male/fe-
male), previous chronic heart failure (yes/no), previous
chronic obstructive pulmonary disease (COPD) (yes/no),
cardiac arrest witnessed (yes/no), bystander cardiopulmo-
nary resuscitation (yes/no), initial rhythm shockable (yes/
no), time to ROSC, admission GCS-M 1 vs 2–5, circula-
tory shock, TTM-treatment (low, 32–34 degrees Celsius
(°C) versus high, 35–37 °C) and pH on admission as fixed
effects and treatment site as a random effect. None of the
independent variables included in our models were highly
correlated. We conducted two-sided tests and considered
a P-value < 0.05 as significant. We included patients with
complete data (PaO2 and/or PaCO2 and CPC at discharge
registered) in the primary and secondary analyses. How-
ever, for our long term outcome sensitivity analysis, we
imputed missing outcome (last observation (CPC at dis-
charge) carried forward). Analyses were conducted using
R: A language and environment for statistical Computing
(version 3.3.3 R Foundation for Statistical Computing,
Vienna, Austria) [33].
Results
The INTCAR 2.0 database included 2162 OHCA patients
who were assessed for eligibility. Of this cohort, we ex-
cluded 27 patients who experienced OHCA but were not
unconscious on admission. The remaining 2135 patients
were included in our final analysis (Fig. 1). Baseline data
for this group is displayed in Table 1. Baseline data for the
different PaO2 and PaCO2 exposure groups are displayed
in the Additional File, Tables 1 and 2. Six hundred eight-
een (28.9%) patients experienced a good outcome and
1517 (71.1%) a poor outcome. Eight hundred twenty-eight
(38.8%) patients were alive at discharge, while 1307
(61.2%) were dead. At 6-month follow-up the outcome of
634 (29.7%) patients was good, whereas 1501 (70.3%) pa-
tients had a poor outcome in the cohort with imputed
data. The cohort without imputation showed a good out-
come in 450 (24.3%) and a poor outcome in 1400 (75.7%)
patients. All patients received TTM treatment during the
first 24 h after ROSC, 1673 (78.4%) to target temperature
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32–34 °C and 462 (21.6%) to 35–37 °C. Three hundred and
fifty-seven (18.7%) patients were exposed to hyperoxemia,
343 (17.9%) patients to hypoxemia and 76 (3.9%) to both,
while 670 (34.5%) patients experienced hypercapnemia, 458
(23.6%) hypocapnemia and 222 (11.4%) both. During the first
24 h after OHCA, median highest PaO2 was 25.7 (IQR 18.5–
38.1) kPa, median lowest PaO2 was 10.0 (IQR 8.1–12.7) kPa
and median lowest PaCO2 was 4.3 (IQR 3.7–4.9) kPa.
In our primary analyses we found, after adjustment, neither
hyperoxemia nor hypoxemia exposure in the first 24h after
ROSC to be associated with poor neurological outcome (all
analyses, P=0.13–0.44) (Table 2). Exposure to hyper- or hypo-
capnemia during the first 24 h after ROSC was also not associ-
ated with poor outcome (all analyses, P=0.18–0.49) (Table 2).
In our secondary analysis the outcomes for patients ex-
posed to the combination of hyperoxemia with hypocap-
nemia showed no association with poor neurological
outcome (P = 0.11, Table 3). The exposure combination of
hypercapnemia with PaO2 no-exposure was also not asso-
ciated with poor outcome (P = 0.86, Table 3). Figure 2a
and b depict the adjusted OR with 95% CIs for poor
neurological outcome across ascending and descending
PaO2 cut off values. Figure 2c shows the adjusted OR with
95% CIs for poor neurological outcome across descending
PaCO2 cut off values. We did not detect a significant
threshold value for the onset of an association with poor
outcome in any of these three analyses.
Sensitivity analyses
The results of the sensitivity analysis with all double exposed
patients (hyperoxemia and hypoxemia or hypercapnemia and
hypocapnemia) removed were similar to the results of our pri-
mary analyses (P=0.07–0.29) (Additional File, Table 3). Re-
placing outcome at discharge with long term outcome in our
primary analyses did not change our results significantly, nei-
ther in the dataset without imputed outcome measures (P=
0.14–0.89) nor in the dataset with missing outcome measures
imputed (P=0.13–0.59) (Additional File, Table 4 and 5).
Missing data
244 patients had one or more PaO2 or PaCO2 data points
missing. Comparing this group with the group of patients
with complete PaO2 and PaCO2 data (n = 1891) showed
similar values at baseline (Additional File, Table 6).
Discussion
In this exploratory study testing the associations be-
tween exposure to extreme PaCO2 and PaO2 values and
neurological outcomes at discharge of 2135 patients with
OHCA, we found that exposure to extreme PaO2 and
PaCO2 values was common, but not significantly associ-
ated with neurological outcome after adjusting for in the
context of OHCA-relevant covariates. In our subsequent
analyses, we did not show any significant associations of
combinations of PaO2 and PaCO2 and poor neurological
outcomes. Despite investigating PaO2 values to > 60 kPa
and < 5.0 kPa and PaCO2 values to < 3.5 kPa in our
ascending and descending cut-off point analyses, we did
not identify a numerical threshold for the onset of the
association of each variable with poor neurological
outcome. These findings suggest that PaO2 and PaCO2
may not be directly associated with outcome after
Fig. 1 Patient selection pathway. OHCA = out-of-hospital cardiac arrest, n = number, PaO2 = arterial partial pressure of oxygen, PaCO2 arterial
partial pressure of carbon dioxide, vs = versus
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resuscitation from OHCA. Animal studies have shown
worse neurological outcomes and increased neurological
injury after exposure to hyperoxemia following resuscita-
tion from cardiac arrest and indicate that hyperoxemia
in the post cardiac arrest phase might be harmful [34].
These findings have been corroborated by retrospective
observational human studies [21, 35, 36]. Moreover, a
threshold for the onset of poor outcome has been pro-
posed at 40 kPa [21]. Elmer et al. confirmed the previ-
ously suggested hyperoxemia threshold of 40 kPa for the
onset of poor outcome but also showed that moderate
hyperoxemia (PaO2 13.5–39.9 kPa) was associated with
lower SOFA scores at 24 h, indicating a possibly benefi-
cial effect at these levels [37]. This finding was supported
by a study of Helmerhorst et al. investigating 5258 car-
diac arrest patients, displaying a U-shaped relationship
between PaO2 and outcome and, although not signifi-
cant, the lowest probability of in-hospital death between
13.6–40 kPa [38]. However, not all investigations support
these results [27, 39], and studies are frequently of retro-
spective design, correct for different confounders and in-
vestigate mixed IHCA and OHCA cohorts.
A recent multi-center study of 280 patients across 6
hospitals in the United States by Roberts et al., sampled
blood gases at 1 and 6 h after ROSC and found that early
hyperoxemia was associated with poor outcome at dis-
charge. The investigators also substantiated the sug-
gested threshold for the onset of poor outcome at 40
kPa. We investigated comparable PaO2 levels in our
study and although our results were not significant, the
point estimates of our primary analyses indicate higher
probabilities for poor outcome in the hyperoxemia
group but also in the hypoxemia group. We did not
identify a significant threshold for the onset of poor
neurological outcome in our cut-off analysis but the
lowest probability of poor outcome was in the group ex-
posed to a PaO2 of up to 20 kPa which was similar to
the risk ratio analysis by Roberts et al. Nevertheless,
there are noteworthy differences between the investiga-
tions; our cohort was significantly larger than Roberts
et al. and we included exclusively OHCA patients in
order to increase homogeneity regarding cardiac arrest
etiology. Furthermore, and most importantly, Roberts
et al. sampled blood gases according to a prospective
protocol over the first 6 h whereas our study evaluated
the most extreme blood gas values during the first 24 h
after ROSC.
Exposure to hypercapnemia or hypocapnemia in the
post cardiac arrest phase is common [17, 18, 25, 40] and
hypocapnemia has frequently been associated with poor
outcome [17, 18, 41] while hypercapnemia exposure has
been associated with poor outcome [17, 30, 38, 42], good
outcome [12, 13, 18, 24] or no difference in outcome
[25, 41]. In an analysis of 9176 adult OHCA patients
Table 2 Association of exposure to extreme PaO2 and PaCO2
values with poor neurological outcome
Analysis OR 95% CI P-Value
Hyperoxemia versus PaO2 no-exposure 1.33 0.92–1.92 0.13
Hyperoxemia versus no-hyperoxemia 1.25 0.88–1.77 0.22
Hypoxemia versus PaO2 no-exposure 1.26 0.87–1.82 0.22
Hypoxemia versus no-hypoxemia 1.15 0.81–1.64 0.44
Hypercapnemia versus PaCO2 no-exposure 0.89 0.64–1.24 0.49
Hypercapnemia versus no-hypercapnemia 0.86 0.64–1.15 0.31
Hypocapnemia versus PaCO2 no-exposure 1.28 0.90–1.83 0.18
Hypocapnemia versus no-hypocapnemia 1.23 0.91–1.66 0.18
OR odds ratio, 95% CI 95% confidence interval, PaO2 arterial partial pressure of
oxygen, PaCO2 arterial partial pressure of carbon dioxide. Hyperoxemia =
PaO2 > 40 kPa, Hypoxemia = PaO2 < 8.0 kPa, Hypercapnemia = PaCO2 > 6.7 kPa,
Hypocapnemia = PaCO2 < 4.0 kPa. PaO2 no-exposure = 8.0–40 kPa
PaCO2 no-exposure = 4.0–6.7 kPa
Table 1 Baseline characteristics of patients included in the PaO2
and PaCO2 analyses, n = 2135
Demographic characteristic Value
Age in years, mean (SD) 61.09 (15.9)
Male sex, n (%) 1432 (67.1)
Medical history
Previous myocardial infarction n (%) 370 (17.3)
Chronic heart failure n (%) 367 (17.2)
COPD n (%) 344 (16.1)
Cerebro vascular disease n (%) 196 (9.2)
Diabetes mellitus n (%) 521 (24.4)
Obesity n (%) 268 (15.3)
Cardiac arrest characteristic
Witnessed cardiac arrest n (%) 1591 (75.6)
Bystander CPR n (%) 1385 (65.5)
Bystander defibrillation n (%) 123 (5.8)
Initial rhythm shockable n (%) 1022 (50.0)
Time to ROSC (min), median (IQR) 29 (21–48)
Characteristic on arrival
Sedated on arrival n (%) 437 (21.7)
GCS Motor 1 n (%) 1544 (79.4)
Circulatory shock on admission n (%) 902 (44.2)
Admission pH, median (IQR) 7.2 (7.1–7.3)
Admission lactate, mmol/l, median (IQR) 6.4 (3.2–10.2)
Bicarbonate on admission, mmol/l, median (IQR) 18.0 (14.5–21.0)
n number, SD standard deviation, IQR interquartile range, % percent, mmol/l
millimole per liter, CPR cardio pulmonary resuscitation, ROSC return of
spontaneous circulation, COPD chronic obstructive pulmonary disease, GCS
Glasgow coma scale, PaO2 arterial partial pressure of oxygen, PaCO2 arterial
partial pressure of carbon dioxide, all % are presented as valid percent
Ebner et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine           (2020) 28:67 Page 5 of 9
in the ROC-network, Wang et al. showed that hyper-
capnemia at any time-point within the first 24 h after
OHCA and hypocapnemia towards the end of the
first 24 h was associated with increased in-hospital
mortality. Our study employed the same cut-off levels
for hypercapnemia and hypocapnemia as Wang et al.,
but the prevalence of hypercapnemia and hypocapne-
mia were lower in our analysis (34.5% versus 51.0 and
23.6% versus 30.6%, respectively). The overall in-
hospital mortality of Wang et al. was similar to our
proportion of patients with CPC5 at discharge (67.3%
versus 61.2%), but we did not achieve significant re-
sults in our analyses, and somewhat contrary to the
ROC-network analysis our point estimates indicate a
lower probability for poor outcome in the group ex-
posed to hypercapnemia. However, the studies are not
entirely comparable; Wang et al. included significantly
more patients and analyzed the first, last or any arter-
ial blood gas measurement during the first 24 h of
hospitalization, while our study analyzed the most ex-
treme values within 24 h of ICU admission. Moreover,
Wang et al. did not correct for in-hospital care such
as induced hypothermia or physiological parameters
as pH.
Considering the results of the studies investigating PaO2
or PaCO2, the exposure to combinations of extreme PaO2
and PaCO2 values might also be associated with neuro-
logical outcome. Vahersaalo et al. found in a cohort of 409
OHCA patients the combination of moderate hypercapne-
mia and mild hyperoxemia to be associated with improved
neurological outcome. We investigated hypercapnemia in
combination with PaO2 8.0–40 kPa, but were not able to
show an association with an improved outcome in this
group. Treatment with induced hypothermia to 32–34 °C
might influence CO2 solubility and represent a potential
bias between analyses, but the 32–34 °C groups were of
similar size in both studies (71% versus 78.4%). Neverthe-
less, there were significant differences, most notably,
Vahersaalo et al. measured mean PaO2 and PaCO2 values
in different ranges whereas we analyzed exposure to the
most extreme values.
As shown above, studies investigating extreme PaO2
and PaCO2 value exposure after cardiac arrest differ in in-
clusion criteria and the time frame after ROSC, objectives
Fig. 2 a-c. Forest plot showing the adjusted ORs (bullet points) with 95% CI (horizontal lines) for poor neurological outcome (CPC 3–5) across
ascending PaO2 cut-off points (a), descending PaO2 cut-off points (b) and descending PaCO2 cut-off points (c). ORs and CIs are presented on a
logarithmic scale. For (a), OR above 1.0 indicates worse outcome above the PaO2 threshold. For (b) and (c), OR above 1.0 indicates worse
outcome under the PaO2 or PaCO2 threshold. OR = Odds ratio, 95% CI = 95% confidence interval, CPC = cerebral performance category, PaO2 =
arterial partial pressure of oxygen, PaCO2 = arterial partial pressure of carbon dioxide. All analyses were adjusted for co-variates
Table 3 Association of PaO2 and PaCO2 combinations with poor neurological outcome
Analysis OR 95% CI P-Value
Hyperoxemia and hypocapnemia versus PaO2 and PaCO2 no-exposure 1.67 0.89–3.14 0.11
PaO2 no-exposure and hypercapnemia versus PaO2 and PaCO2 no-exposure 0.96 0.63–1.48 0.86
OR odds ratio, 95% CI 95% confidence interval, PaO2 arterial partial pressure of oxygen, PaCO2 arterial partial pressure of carbon dioxide. Hyperoxemia = PaO2 > 40
kPa, Hypoxemia = PaO2 < 8.0 kPa, Hypercapnemia = PaCO2 > 6.7 kPa, Hypocapnemia = PaCO2 < 4.0 kPa. PaO2 no-exposure = 8.0-40 kPa,
PaCO2 no-exposure = 4.0–6.7 kPa
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and results. Moreover, short term variability in vascular
tone and acid-balance due changes in the fraction of in-
spired oxygen (FiO2) or respiratory rate is commonly not
accounted for [23, 43]. It seems also important to point
out that the possible protective and harmful properties as-
sociated with exposure to extreme PaO2 and PaCO2
values are still of a largely hypothetical nature. Hypercap-
nemia increases CBF and might improve outcome by opti-
mizing CBF and CDO2 after OHCA as suggested by
Eastwood et al. [13, 15]. Hypercapnemia is also an effect-
ive anticonvulsant, suppressing neuronal activity in the
central nervous system and potentially reducing neuronal
metabolic demands following ROSC, but so far, hypercap-
nemia has failed to show an association with favorable
EEG patterns after OHCA [9, 44–46]. The optimal dose of
hypercapnemia in the post OHCA phase, if favorable, is
not known. Two randomized controlled pilot-studies in-
vestigating high normal PaCO2 (5.8–6.0 kPa) and mild
hypercapnemia (6.7–7.3 kPa) have used neuron specific
enolase (NSE) as a surrogate marker of neuronal injury
[13, 44]. NSE was significantly reduced in patients exposed
to mild hypercapnemia, while high normal PaCO2 expos-
ure was not associated with NSE levels after OHCA. Al-
though, consistent high quality evidence is lacking, there
are no indicators of harmful effects of controlled hyper-
capnemia exposure after OHCA [13, 25, 44]. However, the
results of the present study conflict with results from pre-
vious investigations and support the need for further ran-
domized trials [47, 48].
Neuronal metabolic failure due to hypoxemia during
the no-flow period of the OHCA is the principal cause
of cerebral damage, but also hyperoxemia following
ROSC has been associated with neuronal injury, possibly
due to increased production of ROS, lipid oxidation and
decreased CBF [3, 49, 50]. In a randomized pilot trial,
moderately elevated PaO2 levels (20–25 kPa) did not in-
fluence NSE levels or neurological outcome after 6
months and exposure to PaO2 levels ≥40 kPa following
ROSC has not been investigated in a prospective ran-
domized manner in humans [44]. However, randomized
animal trials and observational human studies suggest
harmful effects [12, 21, 34, 36, 37]. Our results do not
support these findings entirely and randomized studies
investigating increased levels of PaO2 in the post OHCA
phase would be a possible way to further test the effect
of PaO2 on outcome.
Our study has several limitations. Firstly, due to its ob-
servational design, the results are hypothesis generating
and we cannot make causality statements. Secondly, we
evaluated the most deviant PaO2 or PaCO2 values in the
first 24 h after ROSC and were not able to analyze the
exact exposure time-point, duration or to correct for
acid-base parameters at the same time-point. Thirdly, in
the statistical analyzes, our P-values were not significant
on the 0.05 threshold level, but considering the direction
of our point estimates and the width of the 95% CI’s, we
cannot exclude a possible type II error and that there
are associations that may have been statistically signifi-
cant in a larger population [51]. We did not correct for
FiO2 or PaO2/FiO2 ratios since FiO2 was not registered
in the INTCAR 2.0 protocol and the PaO2/FiO2 ratio is
rather an indicator for altered lung function, already
accounted for by correcting for pre-existing COPD. The
strengths of this study are the multicenter prospective
design with 22 participating centers over two continents,
a large cohort with over 2000 OHCA patients with ex-
tensive data regarding cardiac arrest characteristics and
medical background and few excluded patients, as well
as no missing outcome data in our primary and second-
ary analyses.
In summary, this study did not show an independent
association of exposure to extreme PaO2 and PaCO2
values during the first 24 h after ROSC and neurological
outcome at hospital discharge. The results of studies in-
vestigating exposure to extreme PaO2 and PaCO2 values
vary widely and there is currently no consensus if ex-
treme PaO2 or PaCO2 values are harmful, beneficial or
innocuous to the post OHCA patient. The results of fu-
ture prospective randomized studies are warranted be-
fore the existing recommendations on PaO2 and PaCO2
levels in the post OHCA phase can be revised [47, 52].
Conclusion
In a large cohort of patients resuscitated from OHCA, ex-
posure to extreme PaO2 and PaCO2 values in the first 24
h after ROSC occurred commonly, but was not independ-
ently associated with neurological outcome at discharge.
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